DocGo Inc.

NASDAQ:DCGO

Medical - Care Facilities

Healthcare
$0.71 -4.29%

-$0.02 today

Market cap
$70.14M
Beta
1.00
P/E (TTM)
-0.3
EPS (TTM)
-$1.90
52W Low $0.49High $1.78

Volume 1.64M

Average 0.87M

DCGO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

DocGo Inc.NASDAQ: DCGO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $3.71M rose 1.8% year over year, behind the +6.1% change in trailing-twelve-month research & development. Sequentially, it fell 1.8% from the prior quarter. Over 3 fiscal years it compounded at +36.1% a year.

Context

  • Research & development amounted to 4.2% of revenue in FY2025, up 2.3 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.8% toward the trailing-twelve-month pace of +6.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.71M-1.8% QoQ
Last fiscal yearDec 2025
$13.56M+17.0% YoY
LTMMar 2026
$13.63M+6.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.8%——
1 year+17.0%——
3-year CAGR+36.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
13.56M USD
Year-over-year change
+17.0%
4-year CAGR
+42.2%

Research & Development vs competitors

How DCGO compares with its peers on the latest reported figures

  • DCGO's LTM Mar 2026 research & development of $13.63M is the 8th highest of the 9 companies compared; the peer median is $25.17M.
  • Its year-over-year change of +6.1% is the 4th highest of 9, against a peer median of -7.4%.
  • Research & development amounts to 4.5% of revenue for DCGO, versus a peer median of 447.6%.
DCGO Competitors Peer median
Research & Development for DCGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COYACoya Therapeutics, Inc.LTM Mar 2026$3.68B +26273.1%+50.2%46313.4%
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M -19.9%-12.2%86.2%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$79.09M -33.8%+0.5%473.0%
OVIDOvid Therapeutics Inc.LTM Mar 2026$30.07M -8.9%+1.3%422.2%
IMMXImmix Biopharma, Inc.LTM Mar 2026$20.26M +102.3%+57.1%—
RCELAVITA Medical, Inc.LTM Mar 2026$20.18M -5.9%+14.6%27.9%
VANIVivani Medical, Inc.LTM Mar 2026$18.17M +11.9%+8.6%—
DCGODocGo Inc.LTM Mar 2026$13.63M +6.1%+36.1%4.5%
MBOTMicrobot Medical Inc.LTM Mar 2026$6.11M -11.4%-6.7%5814.3%
Peer median (excluding DCGO) $25.17M-7.4%+4.9%447.6%

Competitors are the stored peer set for DCGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue318.72M440.52M624.29M616.56M322.2M
Cost of Revenue208.97M285.79M428.91M402.98M223.44M
Gross Profit109.75M154.72M195.38M213.57M98.76M
Gross Margin34.4%35.1%31.3%34.6%30.7%
Research & Development3.32M5.38M10.86M11.59M13.56M
Selling, General & Admin83.56M116.94M153.04M157.41M158.69M
Operating Expenses94.39M132.89M180.33M184.89M187.91M
Depreciation & Amortization7.51M10.57M16.43M15.88M15.66M
EBITDA28.07M33.35M32.73M45.56M(170.82M)
EBITDA Margin8.8%7.6%5.2%7.4%-53.0%
Operating Income15.36M21.83M15.05M28.69M(89.16M)
Operating Margin4.8%5.0%2.4%4.7%-27.7%
Interest Income0762.69K1.68M236.95K0
Interest Expense763.03K002.17M1.01M
Other Income / Expenses4.44M950.26K1.24M(939.72K)(98.34M)
Income Before Tax19.8M22.78M16.29M27.75M(187.5M)
Pre-Tax Margin6.2%5.2%2.6%4.5%-58.2%
Income Tax Expense615.7K(7.96M)6.24M14.39M8.87M
Net Income23.74M34.58M6.86M19.99M(182.4M)
Net Margin7.4%7.9%1.1%3.2%-56.6%
EPS (Basic)0.300.340.070.20(1.84)
EPS (Diluted)0.250.340.060.18(1.84)
Weighted Avg Shares80.29M101.23M103.51M102.4M99.07M
Weighted Avg Shares (Diluted)94.86M102.98M105.62M109.42M99.07M

DocGo Inc.

NASDAQ:DCGO

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.